Table 2

Data in high-risk cohorts for patients undergoing autologous transplant

TrialTime pointEFS all patientsEFS/PFS t(4;14)PFS del(17p)OS % all patientsOS % t(4;14)OS % del(17p)
VD vs VAD35,364 y36 mo28 mo14 mo776349
NR16 moNR823250
VTD vs TD373 y74%69%NR86NRNR
63%37%NR84NRNR
PAD vs VAD393 y28 mo25 mo26 mo856669
35 mo21 mo12 mo804417
RVD→RVD*13 y32 moNR28 mo93%NR94%
  • EFS, event-free survival; NR, not reported; PAD, bortezomib, doxorubicin, and dexamethasone.

  • * Only high-risk patients were enrolled.